Can Selective Serotonin Reuptake Inhibitors (SSRIs) cause Transient Ischemic Attacks (TIAs)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 14, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

SSRIs are not directly associated with causing TIAs, and their potential mild blood-thinning effects may even offer some protection against vascular events. When considering the relationship between SSRIs and TIAs, it's essential to focus on the most recent and highest quality evidence available. According to the 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack by the American Heart Association/American Stroke Association 1, the primary concern for individuals at risk of TIA or stroke is managing underlying vascular risk factors.

Some key points to consider include:

  • The annual incidence of TIA is approximately 240,000 individuals in the United States 1.
  • The risk of recurrent stroke or TIA can be mitigated with appropriate secondary stroke prevention strategies.
  • While SSRIs may have a mild effect on platelets, which could theoretically increase bleeding risk, they are not typically considered a direct cause of TIAs.
  • Patients with a history of stroke, TIA, or significant vascular risk factors should discuss the benefits and risks of SSRI therapy with their healthcare provider before starting these medications.

In clinical practice, the benefits of SSRIs in managing depression and anxiety often outweigh the potential risks, especially when considering the low likelihood of directly causing a TIA. However, it's crucial for patients to be aware of the symptoms of TIA, such as sudden weakness, numbness, difficulty speaking, or vision changes, and to seek immediate medical attention if these symptoms occur. By prioritizing the management of vascular risk factors and carefully weighing the benefits and risks of SSRI therapy, healthcare providers can help minimize the risk of TIA and other vascular events in their patients.

From the Research

SSRIs and TIA

  • There is evidence to suggest that selective serotonin reuptake inhibitors (SSRIs) may be associated with an increased risk of cerebrovascular events, including transient ischemic attack (TIA) 2.
  • A case report described a patient who developed reversible cerebral vasoconstriction syndrome (RCVS) while taking fluoxetine, an SSRI, which led to cerebral ischemia and TIA-like symptoms 2.
  • Another study found that fluoxetine was associated with an increased risk of adverse outcomes, including falls, bone fractures, seizures, and hyponatremia, in patients with a history of stroke 3.
  • However, it is unclear whether SSRIs directly cause TIA, as the evidence is largely based on case reports and observational studies.

Mechanisms and Associations

  • The exact mechanism by which SSRIs may contribute to TIA is not fully understood, but it may be related to their effects on serotonin receptors and cerebral blood vessels 2.
  • SSRIs may also interact with other medications, such as statins, which are commonly used to prevent stroke, and increase the risk of adverse outcomes 4.
  • Family history of cardiovascular disease, including stroke, may also play a role in the risk of recurrent events after TIA or ischemic stroke 5.

Clinical Implications

  • Clinicians should be aware of the potential risks and benefits of SSRIs in patients with a history of cerebrovascular disease or TIA 2, 3.
  • Patients taking SSRIs should be monitored closely for signs of cerebrovascular events, and alternative treatments should be considered if necessary 2, 3.
  • Further research is needed to fully understand the relationship between SSRIs and TIA, and to determine the best course of treatment for patients with a history of cerebrovascular disease.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Reversible Cerebral Vasoconstriction Syndrome Associated With Fluoxetine.

Journal of the Academy of Consultation-Liaison Psychiatry, 2021

Research

Fluoxetine for Stroke: A Mixed Bag of Outcomes.

The Journal of clinical psychiatry, 2021

Research

Family History is Related to High Risk of Recurrent Events after Ischemic Stroke or Transient Ischemic Attack.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2022

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.